Short ReportHeart failure hospitalisation relative to major atherosclerotic events in type 2 diabetes with versus without chronic kidney disease: A meta-analysis of cardiovascular outcomes trials
Introduction
Atherosclerotic major adverse cardiovascular (CV) events (MACE) are collectively the most common CV events in people with type 2 diabetes, as demonstrated in our recent meta-analysis of contemporary CV outcomes trials [1]. However, this work also showed that in trials enriched with people with chronic kidney disease (CKD; i.e. CARMELINA [2] and CREDENCE [3]), hospitalisation for heart failure (HHF) occurred as often, or more often, than nonfatal MACE events. In the current era of diabetes treatment, selection between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose co-transporter-2 (SGLT2) inhibitors to treat type 2 diabetes is partly dictated by which CV outcomes may be considered the “gravest threat” [4]. Knowing whether CKD materially shifts the relative appearance of HHF versus MACE may help to inform treatment decisions. In this analysis, we compared placebo-arm incidence rates of HHF, MACE, myocardial infarction (MI), and stroke in CV outcome trial subgroups with and without baseline CKD (manifest as reduced eGFR or micro-/macro-albuminuria).
Section snippets
Data sources
Since regulatory authorities mandated in 2008 that new diabetes therapies demonstrate CV safety [5], 16 placebo-controlled CV outcomes trials have been published in type 2 diabetes covering the three new classes of GLP-1RAs, SGLT2 inhibitors, and dipeptidyl-peptidase-4 (DPP4) inhibitors. As part of data sourcing/extraction for a preceding meta-analysis [1], we identified seven trials with reports of CV outcomes stratified by baseline eGFR categories, and five stratified by levels of baseline
Results
Subgroups with eGFR <60 were older (pooled mean age 68 vs. 63 years with normal eGFR), had a lower proportion of men (61% vs. 67%), and a higher proportion with prior heart failure (19% vs. 12%); however, subgroups with reduced vs. normal eGFR were similar in terms of haemoglobin A1c (8.0% vs. 8.1%) and prior CV disease history (86% vs. 82%). Albuminuria subgroups were characterised by a small increase in mean age (65 vs. 64 years with normoalbuminuria), a higher proportion of men (70% vs.
Discussion
CKD was associated with higher incidence of all CV outcomes in type 2 diabetes, irrespective of its manifestation as kidney dysfunction (eGFR < 60) or kidney damage (albuminuria). However, the magnitude of increase was significantly greater for HHF than for MACE. This translated to a shift in the relative frequencies of HHF and MACE events, so that HHF appeared at a similar frequency to MI – and was more common than stroke – in the setting of CKD.
Although the relatively small number of trials
Conclusion
With the advent of glucose-lowering therapies with differential efficacy for HHF and MACE outcomes, CKD markers – particularly albuminuria – may be useful in identifying people with type 2 diabetes at higher/lower risk of specific CV events.
Conflicts of interests
JWS and DJM declare no competing interests relevant to this paper. Dr Jonathan Shaw reports receiving honoraria for lectures and advisory boards from: Astra Zeneca; Sanofi; Novo Nordisk; MSD; Eli Lilly; Abbott; Mylan; Boehringer Ingelheim; and Pfizer.
Acknowledgements
This work was supported by the National Health and Medical Research Council of Australia (NHMRC; APP1107361 to DJM and APP1173952 to JES) and the Victorian Government’s Operational Infrastructure Support Program. Neither funding organisation had any role in study design/conduct, collection/interpretation of data, preparation/review of the manuscript, nor in the final decision to submit for publication.
References (8)
- et al.
Incidence of hospitalization for heart failure relative to major atherosclerotic events in type 2 diabetes: a meta-analysis of cardiovascular outcomes trials
Diabetes Care
(2020) - et al.
Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial
Jama
(2019) - et al.
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
N Engl J Med
(2019) - et al.
Update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Diabetologia
(2019)
Cited by (5)
Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
2021, Cardiovascular Diabetology